Interferon beta (IFN-beta)
Rules-Based Medicine’s (RBM) internally developed and manufactured ultrasensitive immunoassay to interferon beta (IFN-β, IFN-beta) on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of IFN-β in serum or plasma. High circulating type I interferons (IFN-α/IFN-β) are associated with increased clinical severity of diseases, including viral infection and some autoimmune diseases.
IFN-β belongs to the family of type I interferons sharing approximately 35% sequence homology to the interferon-alpha gene family. IFN-β is produced and released by nearly all cell types to stimulate the human anti-microbial response. The biological effects of IFN-β are mediated through binding to a heterodimeric transmembrane IFN-α/β receptor to activate JAK1 and TYK2 which leads to phosphorylation of STAT1 and STAT2 and transcription of several hundred IFN-regulated genes. In addition to antiviral and antimicrobial properties, type I interferons are known to play important roles against tumor development, and IFN-β has been tested in several clinical trials for the treatment of melanoma and colorectal cancer.
Unlike other autoimmune diseases, multiple sclerosis (MS) patients have lower levels of circulating type I IFNs, and IFN-β is a widely used immunomodulatory agent approved by the FDA as first-line therapy for the treatment of relapsing-remitting MS. Sensitive assays to detect endogenous levels of IFN-β may help with future research targeting type I interferon pathways in various diseases.
Swiss-Prot Accession Number: P01574
(Serum and Plasma)
|Serum or plasma||Other fluids**|
|Interferon beta (IFN-beta)||0.16 pg/mL||0.04 pg/mL||100 µL||150 µL|
* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.
** Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.